Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 71 to 80 of 2245 total matches.

Siponimod (Mayzent) - A New Drug for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • May 06, 2019  (Issue 1571)
– Novartis), a sphingosine 1-phosphate (S1P) receptor modulator, for oral treatment of adults with relapsing ...
The FDA has approved siponimod (Mayzent – Novartis), a sphingosine 1-phosphate (S1P) receptor modulator, for oral treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). Siponimod is the second S1P receptor modulator to be approved in the US; fingolimod (Gilenya), which is approved for oral treatment of relapsing forms of MS in patients ≥10 years old, was the first. The purine antimetabolite cladribine (Mavenclad) was also...
Med Lett Drugs Ther. 2019 May 6;61(1571):70-2 | Show Introduction Hide Introduction

Generic Topical Corticosteroids

   
The Medical Letter on Drugs and Therapeutics • May 06, 1988  (Issue 765)
(Volume 28, page 1, 1986), the prediction that generic drugs newly approved in the USA under more relaxed ...
Since the last Medical Letter review of generic drugs (Volume 28, page 1, 1986), the prediction that generic drugs newly approved in the USA under more relaxed federal regulations will probably be as reliable as brand-name drugs has generally been accurate. Few well-documented generic product failures have been reported. Recently, however, the equivalence of generic topical corticosteroids has been questioned.
Med Lett Drugs Ther. 1988 May 6;30(765):49-50 | Show Introduction Hide Introduction

Another Extended-Release Alpha2-Agonist for ADHD

   
The Medical Letter on Drugs and Therapeutics • Feb 07, 2011  (Issue 1357)
for this indication; guanfacine hydrochloride (Intuniv) was the first,1 but only clonidine is approved for use ...
The FDA has approved an extended-release formulation of clonidine hydrochloride (Kapvay– Shionogi) for treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6-17 years old. It is the second alpha2-adrenergic agonist approved for this indication; guanfacine hydrochloride (Intuniv) was the first, but only clonidine is approved for use with stimulants.
Med Lett Drugs Ther. 2011 Feb 7;53(1357):10-2 | Show Introduction Hide Introduction

Terconazole For Candida Vaginitis

   
The Medical Letter on Drugs and Therapeutics • Dec 30, 1988  (Issue 782)
in plasma (BF Kennedy and H Friedmann, Gynakol Rundsch, 25 suppl 1:26, 1985). ANTIMICROBIAL ACTIVITY ...
Terconazole (Terazol - Ortho), an imidazole derivative, was recently marketed in the USA for treatment of vulvovaginal candidiasis. It is available both as a 0.4% vaginal cream (Terazol 7) and in 80-mg vaginal suppositories (Terazol 3).
Med Lett Drugs Ther. 1988 Dec 30;30(782):118-9 | Show Introduction Hide Introduction

Glucagon Nasal Powder (Baqsimi) for Severe Hypoglycemia

   
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019  (Issue 1581)
see' mee SEVERE HYPOGLYCEMIA – Hypoglycemia is classified as level 1 (blood glucose ≥54 and ...
The FDA has approved glucagon nasal powder (Baqsimi – Lilly) for treatment of severe hypoglycemia in patients ≥4 years old with diabetes. Baqsimi is the first noninjectable glucagon formulation to become available in the US. Injectable glucagon emergency kits (GlucaGen Hypokit, and generic) have been available for years, but they require reconstitution of the lyophilized powder by the caregiver immediately before injection. An injectable glucagon formulation that does not require reconstitution was recently approved by the FDA (Gvoke) and is expected to become available...
Med Lett Drugs Ther. 2019 Sep 23;61(1581):148-9 | Show Introduction Hide Introduction

In Brief: New Meningococcal Serogroup B Vaccination Recommendations

   
The Medical Letter on Drugs and Therapeutics • Nov 30, 2020  (Issue 1612)
on Immunization Practices (ACIP) has issued new recommendations for meningococcal vaccination.1 Booster ...
The Advisory Committee on Immunization Practices (ACIP) has issued new recommendations for meningococcal vaccination. Booster vaccination against Neisseria meningitidis serogroup B (MenB) is now recommended in persons at increased risk for meningococcal disease (see Table 1). MenB booster doses were not recommended previously for any population.
Med Lett Drugs Ther. 2020 Nov 30;62(1612):191-2 | Show Introduction Hide Introduction

Linagliptin/Metformin (Jentadueto) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • May 14, 2012  (Issue 1390)
require treatment with multiple drugs.1 Linagliptin is a dipeptidyl peptidase-4 (DDP-4) inhibitor like ...
Linagliptin (Tradjenta) and metformin (Glucophage, and others) are now available as a fixed-dose combination (Jentadueto – Boehringer Ingelheim/Lilly) for oral treatment of type 2 diabetes in adults. Metformin is generally the preferred first-line agent for treatment of type 2 diabetes, but most patients eventually require treatment with multiple drugs. Linagliptin is a dipeptidyl peptidase-4 (DDP-4) inhibitor like sitagliptin (Januvia) and saxagliptin (Onglyza). Both sitagliptin and saxagliptin are also available in fixed-dose combinations with...
Med Lett Drugs Ther. 2012 May 14;54(1390):37-9 | Show Introduction Hide Introduction

Simeprevir (Olysio) for Chronic Hepatitis C

   
The Medical Letter on Drugs and Therapeutics • Jan 06, 2014  (Issue 1433)
COPYRIGHT LAWS 1 The FDA has recently approved 2 new drugs for treatment of chronic hepatitis C virus (HCV ...
The FDA has recently approved 2 new drugs for treatment of chronic hepatitis C virus (HCV) infection. Simeprevir (Olysio – Janssen) is the third oral protease inhibitor to be approved for use in combination with peginterferon and ribavirin for treatment of chronic HCV genotype 1 infection in adults with compensated liver disease. Telaprevir (Incivek) and boceprevir (Victrelis) were approved in 2011 for the same indication. Sofosbuvir (Sovaldi – Gilead), a nucleotide analog polymerase inhibitor that has been approved for use with and without interferon for treatment of multiple HCV...
Med Lett Drugs Ther. 2014 Jan 6;56(1433):1-2 | Show Introduction Hide Introduction

Cetirizine Ophthalmic Solution (Zerviate) for Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020  (Issue 1599)
compresses, and avoidance of eye rubbing and contact lens wearing during symptomatic periods.1 Many ...
A 0.24% ophthalmic solution of the second-generation H1-antihistamine cetirizine (Zerviate – Eyevance) is now available by prescription for treatment of ocular itching associated with allergic conjunctivitis in patients ≥2 years old. Oral cetirizine (Zyrtec, and others), which is used for treatment of allergic conjunctivitis and rhinitis, has been available over the counter (OTC) for years.
Med Lett Drugs Ther. 2020 Jun 1;62(1599):81-3 | Show Introduction Hide Introduction

Tapinarof Cream (Vtama) for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Jun 22, 2022  (Issue 5049)
' uh The FDA has approved Vtama (Dermavant), a 1% cream formulation of the aryl hydrocarbon receptor ...
The FDA has approved Vtama (Dermavant), a 1% cream formulation of the aryl hydrocarbon receptor (AhR) agonist tapinarof, for treatment of adults with plaque psoriasis. It is the first AhR agonist to be approved by the FDA.
Med Lett Drugs Ther. 2022 Jun 22;64(5049):1-3 | Show Introduction Hide Introduction